Coronary disease & ACSRandomised controlled trial
Glycoprotein IIb/IIIa inhibitors in acute myocardial infarction and angiographic microvascular obstruction: the REVERSE-FLOW trial
- Randomised controlled trial
- investigator-initiated
- international
- multicentre
Authors' conclusion
Bailout GP IIb/IIIa inhibition in AMI patients with angiographic MVO failed to reduce the primary endpoint infarct size but decreased CMR-derived MVO and led to an increase in non-fatal bleeding events.
Study context
- Population
- Patients with acute MI and TIMI flow grade ≤ 2 (angiographic microvascular obstruction (MVO)) after primary percutaneous coronary intervention (PCI)
- Participants
- 120 patients
- Comparison
- Glycoprotein (GP) IIb/IIIa inhibitor vs no GP IIb/IIIa inhibitor
- GP IIb/IIIa inhibitorn = 62
- Primary endpoint
- Infarct size (% of left ventricular (LV) mass) by cardiac magnetic resonance (CMR)
Primary result
As reported in the abstract
Infarct size by CMR
P = 0.386
Secondary outcomes
Patients with CMR-derived MVO
P = 0.017
All-cause mortality · 30 days
P = 0.703
Extent of MVO
P = 0.025
Safety
Non-life-threatening bleeding · 30 days
P = 0.016
Original publication
Glycoprotein IIb/IIIa inhibitors in acute myocardial infarction and angiographic microvascular obstruction: the REVERSE-FLOW trial. Eur Heart J. Published 1 September 2024. doi:10.1093/eurheartj/ehae587
Summarised from the published abstract; every number is checked against it